Sinopharm Medical is a state-owned enterprise, which refers to China National Pharmaceutical Industry Research Institute Co., Ltd. It has won the National Science and Technology Progress Award, the China Patent Award, and the Provincial and Ministerial Science and Technology Award for many times. It is affiliated to China National Pharmaceutical Group Co., Ltd.
1. Company Overview
1. Main Business Areas
Engaged in the research and development and services of new drug varieties and new processes, and the training of graduate students in the field of pharmacy.
2. Main business objectives
Since then, we have been adhering to the concepts of being close to the industry, serving the industry and taking root in the industry, with the goal of discovering new drugs for the treatment of major diseases and developing industrialized pharmaceutical processes.
3. Service model
Oriented by pharmaceutical companies and clinical needs, it provides numerous new drug varieties, pharmaceutical technologies and evaluation services to my country's pharmaceutical industry.
4. Research and development results
Successively developed gatifloxacin hydrochloride, itraconazole hydrochloride, pazufloxacin mesylate, milnacipran, bicalutamide, Nearly 20 scientific research results including linezolid, fluvastatin, pitavastatin, roflumilast, esomeprazole sodium, sitagliptin, etc.
2. Scientific and technological advantages
1. There is 1 academician of the Chinese Academy of Engineering, 52 researchers with senior professional titles, 3 academicians of the Chinese Academy of Engineering over the years, and experts who have received special allowances from the State Council. Nearly 90 people.
2. It is one of the first batch of first-level discipline units approved by the State Council to train pharmaceutical graduate students. It currently has 7 master's degree awarding points, 7 doctoral degree awarding points, and 1 postdoctoral mobile station.
3. Involving 9 scientific research directions, including the entire drug R&D innovation chain from new drug discovery to process research and development, from raw material drug synthesis to new preparation research and development, from drug preclinical evaluation research to pharmaceutical industry information services. .
4. More than 1,500 authorized patents, more than 600 existing valid patents, and a total of more than 3,000 scientific research results have been industrialized in 31 provinces, municipalities, and autonomous regions across the country.
5. Received multiple grants from the state and Shanghai, including WHO, National Science and Technology Research, National Major New Drug Creation Project, National 973 Program, Shanghai Venus and Shanghai Natural Science Foundation, etc.
6. Established an industry-leading visual search and analysis function system, with three core journals: "Journal of Chinese Pharmaceutical Industry", "World Clinical Drugs" and "Chinese Journal of New Drugs" as well as "Pharmaceutical Fronts" in English Journal.
7. It has nearly 60,000 square meters of modern facilities and a research team of more than a thousand people located in Shanghai, Nantong, Shenzhen and other places.
8. Passed the GLP certification of NMPA, the GLP inspection of the US FDA, the GLP certification of the Dutch government of the OECD member state, AAALAC certification and CAP certification of the American College of Pathology, etc.
Summary
Sinopharm Pharmaceuticals has made great contributions to solving the livelihood problems of drug accessibility for patients in my country. It is also breaking the monopoly of foreign drugs and improving the development level of my country's pharmaceutical industry. Due efforts have been made.